Inhibrx Biosciences Files 8-K, Posts Updated Corporate Presentation

What Happened Inhibrx Biosciences, Inc. (INBX) announced on September 28, 2026 that it posted an updated corporate presentation to the "Investors" tab of its website (www.inhibrx.com). The presentation is attached to the Current Report on Form 8-K as Exhibit 99.1 and was disclosed under Item 7.01 (Regulation FD Disclosure). The filing was signed by Chief Financial Officer Kelly Deck.

Key Details

• Date posted: September 28, 2026.
• Location: Investors tab on www.inhibrx.com; presentation attached as Exhibit 99.1 to the 8-K.
• Purpose: Presentation is used for investor conferences and meetings to provide business updates and summaries.
• Company note: Inhibrx stated it does not undertake any obligation to update, supplement, or amend the attached presentation.

Why It Matters This 8-K is a disclosure under Regulation FD to ensure broad, public access to Inhibrx’s updated investor materials. For retail investors, the filing signals that the company has refreshed its public investor presentation (which may include pipeline, strategy, or operational highlights) but does not itself constitute an earnings release or other material financial disclosure. Investors who follow INBX should review the posted presentation for the latest corporate overview and any program or strategy details the company highlights.